Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > The Take-Over

<< Previous

Bullboard Posts

Next >>

Comment by Ingiboyon Mar 25, 2024 1:22pm

66 Views

Post# 35951132

RE:RE:The Take-Over

I have reached out to both the CSA and the BCSC. The CSA has forwarded my concern to the BSCS.
Seperately i reached out to the BCSC and received a response from a person who is a Senior Legal Counsel, Legal Services, Corporate Finance.
She will be reviewing this Take-Over Proposal.

I think the point we need to make is this Take-Over Proposal is confusing tho the shareholders and does not adequetly explain the intent of the purchaser.

<< Previous

Bullboard Posts

Next >>

Apolo IV Acquisition and Marviken Ontario sign merger agreement